Shao Xinyu, Cheng Zhengwu, Xu Menglin, Tan Zhuqing, Gao Ling, Wang Junfeng, Zhou Chunli
Department of gastroenterology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou.
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Wannan Medical College.
Medicine (Baltimore). 2019 Dec;98(50):e18370. doi: 10.1097/MD.0000000000018370.
This study aims to assess the relationship between Rab1A expression and clinicopathological parameters and prognosis of patients with human solid cancer by summarizing the studies included.
PubMed, EMBASE, The Cochrane Library, and other sources were searched for relative studies. The risk ratios (RRs) and confidence interval (CI) were used to assess association between Rab1A expression and clinical parameters and prognosis in solid cancer patients.
Eight studies were included in the final analysis with 800 patients. The results revealed that expression of Rab1A was significantly related with differentiation (RR = 0.883, 95%CI = 0.782-0.997, P = .044), lymph node metastasis (RR = 0.835, 95%CI = 0.753-0.926, P = .001), tumor-lymph node-metastasis (TNM) stage (RR = 1.190, 95%CI = 1.071-1.322, P < .001) and tumor size (RR = 0.818, 95%CI = 0.730-0.915, P < .001). What is more, no significant difference was seen in 1-year survival between high and low expression of Rab1A in multiple malignancies (RR = 0.855, 95%CI = 0.697-1.050, P = .136). However, increased Rab1A revealed poorer prognosis with 2-year survival (RR = 0.760, 95%CI = 0.701-0.824, P < .001), 3-year survival (RR = 0.669, 95%CI = 0.604-0.742, P < .001), 4-year survival (RR = 0.622, 95%CI = 0.554-0.698, P < .001) and 5-year survival (RR = 0.525, 95%CI = 0.458-0.698, P < .001). Expression of Rab1A was increased obviously in solid cancer tissues compared with the adjacent normal tissue (RR = 4.78, 95%CI 4.05-5.63, P = .015).
This study revealed Rab1A expression links closely with tumor size, differentiation, lymph node metastasis, TNM stage and poor prognosis of human solid cancer patients. It may act as a biomarker of prognosis and a novel therapeutic target in solid cancer.
本研究旨在通过总结纳入的研究来评估Rab1A表达与人类实体癌患者临床病理参数及预后之间的关系。
检索PubMed、EMBASE、Cochrane图书馆及其他来源的相关研究。采用风险比（RRs）和置信区间（CI）评估Rab1A表达与实体癌患者临床参数及预后之间的关联。
最终分析纳入8项研究，共800例患者。结果显示，Rab1A表达与分化（RR = 0.883，95%CI = 0.782 - 0.997，P = 0.044）、淋巴结转移（RR = 0.835，95%CI = 0.753 - 0.926，P = 0.001）、肿瘤-淋巴结-转移（TNM）分期（RR = 1.190，95%CI = 1.071 - 1.322，P < 0.001）及肿瘤大小（RR = 0.818，95%CI = 0.730 - 0.915，P < 0.001）显著相关。此外，在多种恶性肿瘤中，Rab1A高表达与低表达患者的1年生存率无显著差异（RR = 0.855，95%CI = 0.697 - 1.050，P = 0.136）。然而，Rab1A表达增加提示2年生存率（RR = 0.760，95%CI = 0.701 - 0.824，P < 0.001）、3年生存率（RR = 0.669，95%CI = 0.604 - 0.742，P < 0.001）、4年生存率（RR = 0.622，95%CI = 0.554 - 0.698，P < 0.001）和5年生存率（RR = 0.525，95%CI = 0.458 - 0.698，P < 0.001）预后较差。与癌旁正常组织相比，实体癌组织中Rab1A表达明显增加（RR = 4.78，95%CI 4.05 - 5.63，P = 0.015）。
本研究表明Rab1A表达与人类实体癌患者的肿瘤大小、分化、淋巴结转移、TNM分期及预后不良密切相关。它可能作为实体癌预后的生物标志物和新的治疗靶点。
